MA09.01 LCMC3: Immune Cell Subtypes Predict Nodal Status and Pathologic Response After Neoadjuvant Atezolizumab in Resectable NSCLC
暂无分享，去创建一个
M. Kris | G. Lozanski | M. Seweryn | J. Lee | A. Nicholas | K. Schulze | F. Oezkan | S. Hilz | D. Owen | V. Rusch | D. Carbone | D. Kwiatkowski | B. Johnson | A. Johnson | M. Pietrzak | I. Wistuba | W. Y. Byun | J. Grindheim